RATIONALE: Chronic @entity1068 ( @entity167 ) treatment decreases the motor-impairing effects of @entity7785 and downregulates the cannabinoid type 1 ( @entity14650 ) receptor. However, these studies have been limited to measures of ataxia and analysis of @entity14650 expression from whole-brain or hippocampal preparations. OBJECTIVE: To more fully assess the interactions between @entity1068 and @entity7785 , a tetrad of four well-characterized cannabinoid-induced behaviors (hypolocomotion, antinociception, @entity2332 , and @entity8364 ) was measured in @entity19 following @entity167 treatment. Additionally, immunoblotting assessed @entity14650 protein in tissue from nine brain regions associated with these behaviors and the addiction neurocircuitry. MATERIALS AND METHODS: Male C57Bl/6J @entity19 were administered @entity167 (0, 2, or 4 g/kg; intraperitoneally (i.p.)) twice daily for 10 days. Tetrad behaviors induced by the @entity14650 agonist @entity10024 -2 (3 mg/kg, i.p.) were measured in subjects 1 or 10 days following the last @entity167 injection. In a separate group of animals, tissue was collected at the same time points for immunoblot analysis. RESULTS: @entity167 -treated @entity19 were less sensitive to the hypothermic, hypolocomotive, and antinociceptive effects of WIN, and this effect reversed to control levels over a 10-day abstinence period. @entity167 treatment did not affect WIN-induced @entity8364 . @entity14650 protein expression was significantly altered in several brain areas including the @entity2339 , periaqueductal gray, ventral tegmental area, and cerebellum. CONCLUSIONS: These results show that chronic @entity167 treatment significantly affects the behavioral sensitivity to cannabinoid drugs and alters @entity14650 expression in several brain regions. Furthermore, these effects are selective as some behaviors and brain regions display an altered response while others do not.

Tolerance to cannabinoid-induced behaviors in XXXX treated chronically with @entity1068 .

@entity7785 :: ('MESH:D002186', 'Chemical') :: ['cannabinoids'] @entity167 :: ('CHEBI:16236', 'Chemical') :: ['EtOH'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity10024 :: ('MESH:C070417', 'Chemical') :: ['WIN 55212'] @entity14650 :: ('12801(Tax:10090)', 'Gene') :: ['CB1'] @entity2339 :: ('MESH:D007029', 'Disease') :: ['hypothalamus'] @entity8364 :: ('MESH:D002375', 'Disease') :: ['catalepsy'] @entity1068 :: ('MESH:D000431', 'Chemical') :: ['ethanol'] @entity2332 :: ('MESH:D007035', 'Disease') :: ['hypothermia']
@entity19 :: (10090,Species) :: ['mice']
